MaxCyte, Inc.

MXCT · NASDAQ
Analyze with AI
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Revenue$38,627$41,288$44,261$33,894
% Growth-6.4%-6.7%30.6%
Cost of Goods Sold$7,100$4,742$5,098$3,647
Gross Profit$31,527$36,546$39,163$30,247
% Margin81.6%88.5%88.5%89.2%
R&D Expenses$22,227$23,817$19,514$15,407
G&A Expenses$29,693$30,068$25,829$18,676
SG&A Expenses$56,354$57,043$44,482$31,679
Sales & Mktg Exp.$26,661$26,975$18,653$13,003
Other Operating Expenses$4,143$3,985$2,528$1,349
Operating Expenses$82,724$84,845$66,524$48,435
Operating Income-$51,197-$48,299-$27,361-$18,189
% Margin-132.5%-117%-61.8%-53.7%
Other Income/Exp. Net$10,142$10,376$3,790-$894
Pre-Tax Income-$41,055-$37,923-$23,571-$19,082
Tax Expense$0$0$0$0
Net Income-$41,055-$37,923-$23,571-$19,082
% Margin-106.3%-91.8%-53.3%-56.3%
EPS-0.39-0.37-0.19-0.22
% Growth-5.4%-94.7%13.6%
EPS Diluted-0.39-0.37-0.19-0.22
Weighted Avg Shares Out104,849103,269101,70390,619
Weighted Avg Shares Out Dil104,849103,269101,70390,619
Supplemental Information
Interest Income$10,142$10,376$3,917$151
Interest Expense$0$0$127$1,044
Depreciation & Amortization$4,790$4,171$2,698$1,424
EBITDA-$46,407-$44,128-$24,663-$16,614
% Margin-120.1%-106.9%-55.7%-49%